Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
256 hedge funds and large institutions have $7.65B invested in Karuna Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 85 funds opening new positions, 89 increasing their positions, 68 reducing their positions, and 23 closing their positions.
270% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 23
158% more call options, than puts
Call options by funds: $99.1M | Put options by funds: $38.4M
103% more capital invested
Capital invested by funds: $3.77B → $7.65B (+$3.88B)
75% more funds holding in top 10
Funds holding in top 10: 8 → 14 (+6)
31% more funds holding
Funds holding: 195 → 256 (+61)
31% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 68
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$135M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90.9M |
| 3 |
GA
General Atlantic
New York
|
+$84M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$83.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$80.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$324M |
| 2 |
State Street
Boston,
Massachusetts
|
-$63.1M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$47M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$28.3M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$26.7M |
KRTX Hedge Fund Activity: Q3 2022 in Review
256 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q3 2022, worth a combined $7.65B — up 103% from $3.77B a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new KRTX positions and 23 closed out — a net gain of 62 holders — while 89 added to existing stakes and 68 trimmed.
The largest buyer was Capital International Investors, adding an estimated $135M. The largest seller was Arch Venture Management, cutting an estimated $324M.
- 256 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q3 2022, up from 195 in Q2 2022.
- Funds reported $7.65B of Karuna Therapeutics, Inc. Common Stock stock for Q3 2022, up 103% quarter-over-quarter.
- 85 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q3 2022 and 23 closed out, a net change of +62 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q3 2022 was Capital International Investors, an estimated $135M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q3 2022 was Arch Venture Management, an estimated $324M sold.
Based on aggregated 13F filings for Q3 2022.